Sebela Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: Braintree Laboratories / Sebela Pharmaceuticals | SEBELA IRELAND LTD | Sebela Pharmaceuticals Development LLC | Sebela Pharmaceuticals Inc. | SEBELA WOMENS HLTH

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Nov 20, 2017

First marketed drug

Jun 1, 2013

Last known activity

Feb 24, 2025

Timeline

1970s

Aug 13, 1976
urea— Marketing Organization
Jul 14, 1978
atropine— NDA Secondary Org
Jul 14, 1978
difenoxin— NDA Organization

2010s

Jun 1, 2013
Sebela Pharmaceuticals— Founded
Jun 1, 2018
ContraMed LLC— Acquired

Drugs by trial phase (7 distinct, 8 trials)

Phase 3 (5 own, 1 via acquisition)

Phase 2 (1 own, 0 via acquisition)

polyethylene glycol

Indications

Approved for

Marketed drugs (12)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

ContraMed LLC

Recent trials (8)

NCT05587309Study directorPhase 3Nov 30, 2022
NCT05587322Study directorPhase 3Sep 6, 2022
NCT04457076Lead sponsorPhase 3Dec 31, 2020
NCT04446312Study directorPhase 3Jul 13, 2020
NCT04446299Study directorPhase 3Jul 13, 2020
NCT03785366Lead sponsorPhase 3Dec 17, 2018
NCT03332485Lead sponsorPhase 2Nov 20, 2017
NCT03332485Study directorPhase 2Nov 20, 2017

Details

Founded: Roswell, GA, US Jun 1, 2013
Last known activity: Feb 24, 2025

Designations held

Priority review